Gastric Cancer Drug Pipeline Analysis Report

According to World Cancer Research Fund International, approximately 968,784 new cases of gastric cancer were diagnosed in 2022 across the globe. Data suggests that gastric cancer ranks among the top three most common cancers in 19 countries and continues to be the leading cause of cancer mortality worldwide. The ongoing development of innovative and novel therapies shows a promising future for gastric cancer treatment.

Report Coverage

The Gastric Cancer Drug Pipeline report by Expert Market Research gives comprehensive insights on the gastric cancer drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. Moreover, the analysis based on efficacy and safety measures outcomes published for the trials will be covered including their adverse effects in gastric cancer.

A detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities are covered.

Gastric Cancer Drug Pipeline Outlook

An abnormal cell growth in the stomach can lead to gastric cancer. Before the development of true cancer, pre-cancerous changes occur in the inner lining of the stomach. There are multiple types of gastric cancer which include adenocarcinoma of the stomach, Gastroesophageal Junction Adenocarcinoma (GEJ), gastrointestinal neuroendocrine tumors, and Gastrointestinal Stromal Tumors (GIST).

The treatment for gastric cancer depends on the location of the cancer within the stomach and cancer stage. The treatment options include chemotherapy, targeted therapy and immunotherapy, radiation therapy and others. In 2021, the U.S. Food and Drug Administration amended its accelerated approval of the immunotherapy drug pembrolizumab (Keytruda) for treatment of advanced stomach cancer and gastroesophageal junction (GEJ) cancer.

Research studies shows that the drugs that target HER2 can be used to treat other cancers as well stomach cancer and GEJ cancer. Data suggests that 15% of patients with advanced stomach cancer have HER2-positive tumors. In November 2023, the U.S. Food and Drug Administration approved pembrolizumab combined with chemotherapy as an initial treatment for patients suffering from advanced stomach gastric that is HER2-negative.

The report covers the pathophysiology and epidemiology of gastric cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment in detail.

Gastric Cancer – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of gastric cancer drugs based on various segmentations such as:

By Phase

EMR’s pipeline assessment report covers 50+ drug analysis based on phase.

• Late-Stage Products (Phase III and Phase IV)

• Mid-Stage Products (Phase II)

• Early-Stage Products (Phase I)

• Preclinical and Discovery Stage Products

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analysis based on route of administration.

• Oral

• Parenteral

• Others

Gastric Cancer – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs for Gastric cancer. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover major share of the total gastric cancer clinical trials conducted.

Nivolumab developed by Bristol-Myers Squibb is currently under phase II. The purpose of the study is to assess the safety and efficacy of Nivolumab in combination with Ipilimumab for the treatment of advanced gastric cancer.

Gastric Cancer – Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under gastric cancer pipeline analysis include oral, parenteral and others. The report covers a comparative analysis of the route of administration for each drug in various phases of clinical trials of gastric cancer. According to EMR analysis, the parenteral route accounted for a major share of gastric cancer clinical trials.

Gastric Cancer – Pipeline Assessment – Competitive Dynamics

The EMR report for the gastric cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in gastric cancer clinical trials:

• Bristol-Myers Squibb

• AstraZeneca

• Enzon Pharmaceuticals, Inc.

• Amgen

• Novartis Pharmaceuticals

• Bayer AG

• Daiichi Sankyo Co., Ltd.

• Eisai Co., Ltd.

• Hoffmann-La Roche

• Others

Gastric Cancer – Pipeline Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for gastric cancer. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.

Bemarit uzumab - Amgen

Amgen is conducting phase I clinical trials for bemarituzumab. The purpose of the study is to evaluate the safety and efficacy of bemarituzumab in combination with other anti-cancer therapies to treat multiple cancers including gastric cancer.

Everolimus - Novartis Pharmaceuticals

The purpose of the study is to evaluate the efficacy and safety of RAD001 (Everolimus) monotherapy in patients suffering from advanced gastric cancer.

Trastuzumab - Hoffmann-La Roche

The study is under the observational phase and is sponsored by Hoffmann-La Roche. The primary purpose of the study is to evaluate of Human HER-2 status in gastric cancer.

DS-8201a (DP1) - Daiichi Sankyo Co., L td.

Daiichi Sankyo Co., Ltd. Is conducting phase I trial to assess the safety of DS-8201a in participants suffering from advanced solid malignant tumors.

Key Questions Answered in the Gastric Cancer – Pipeline Assessment Report

• What is the current landscape of gastric cancer pipeline drugs?
• How many companies are developing gastric cancer drugs?
• How many phase III and phase IV drugs are currently present in gastric cancer pipeline drugs?
• Which companies/institutions are leading the gastric cancer drug development?
• What is the efficacy and safety profiles of gastric cancer pipeline drugs?
• What are the opportunities and challenges present in the gastric cancer clinical pipeline landscape?
• Which company is conducting the major trials for gastric cancer drugs?
• What are the geographies covered for clinical trials in gastric cancer?
• What are the clinical trial results of the drugs under development for gastric cancer?
• What are emerging trends in gastric cancer clinical trials?

Related Reports

Global Gastric Ulcer Treatment Market

North America Gastric Cancer Drugs Market

Global Cancer Therapeutics Market

Global Cancer Immunotherapy Market